nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Ocular discomfort—Methotrexate—muscle cancer	0.043	0.043	CcSEcCtD
Apraclonidine—Inflammation—Etoposide—muscle cancer	0.0168	0.0168	CcSEcCtD
Apraclonidine—Lacrimation—Doxorubicin—muscle cancer	0.0144	0.0144	CcSEcCtD
Apraclonidine—Parosmia—Doxorubicin—muscle cancer	0.013	0.013	CcSEcCtD
Apraclonidine—Keratitis—Doxorubicin—muscle cancer	0.013	0.013	CcSEcCtD
Apraclonidine—Pharyngitis—Dactinomycin—muscle cancer	0.0112	0.0112	CcSEcCtD
Apraclonidine—Inflammation—Methotrexate—muscle cancer	0.0101	0.0101	CcSEcCtD
Apraclonidine—Erythema—Dactinomycin—muscle cancer	0.00985	0.00985	CcSEcCtD
Apraclonidine—Vasodilation—Doxorubicin—muscle cancer	0.00962	0.00962	CcSEcCtD
Apraclonidine—Vasodilation procedure—Doxorubicin—muscle cancer	0.00962	0.00962	CcSEcCtD
Apraclonidine—Lacrimation increased—Doxorubicin—muscle cancer	0.00917	0.00917	CcSEcCtD
Apraclonidine—Angiopathy—Vincristine—muscle cancer	0.00917	0.00917	CcSEcCtD
Apraclonidine—Ill-defined disorder—Dactinomycin—muscle cancer	0.00913	0.00913	CcSEcCtD
Apraclonidine—Infestation NOS—Etoposide—muscle cancer	0.00912	0.00912	CcSEcCtD
Apraclonidine—Infestation—Etoposide—muscle cancer	0.00912	0.00912	CcSEcCtD
Apraclonidine—Mediastinal disorder—Vincristine—muscle cancer	0.00911	0.00911	CcSEcCtD
Apraclonidine—Malaise—Dactinomycin—muscle cancer	0.00888	0.00888	CcSEcCtD
Apraclonidine—Mental disorder—Vincristine—muscle cancer	0.00885	0.00885	CcSEcCtD
Apraclonidine—Inflammation—Doxorubicin—muscle cancer	0.00872	0.00872	CcSEcCtD
Apraclonidine—Coordination abnormal—Doxorubicin—muscle cancer	0.00861	0.00861	CcSEcCtD
Apraclonidine—Myalgia—Dactinomycin—muscle cancer	0.00838	0.00838	CcSEcCtD
Apraclonidine—Dermatitis contact—Doxorubicin—muscle cancer	0.00835	0.00835	CcSEcCtD
Apraclonidine—Discomfort—Dactinomycin—muscle cancer	0.00828	0.00828	CcSEcCtD
Apraclonidine—Oedema—Dactinomycin—muscle cancer	0.00803	0.00803	CcSEcCtD
Apraclonidine—Infection—Dactinomycin—muscle cancer	0.00798	0.00798	CcSEcCtD
Apraclonidine—Dry eye—Doxorubicin—muscle cancer	0.00781	0.00781	CcSEcCtD
Apraclonidine—Eye disorder—Etoposide—muscle cancer	0.00765	0.00765	CcSEcCtD
Apraclonidine—Myalgia—Vincristine—muscle cancer	0.00749	0.00749	CcSEcCtD
Apraclonidine—Angiopathy—Etoposide—muscle cancer	0.00743	0.00743	CcSEcCtD
Apraclonidine—Mediastinal disorder—Etoposide—muscle cancer	0.00738	0.00738	CcSEcCtD
Apraclonidine—Abnormal vision—Doxorubicin—muscle cancer	0.00737	0.00737	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00732	0.00732	CcSEcCtD
Apraclonidine—Oedema—Vincristine—muscle cancer	0.00718	0.00718	CcSEcCtD
Apraclonidine—Infection—Vincristine—muscle cancer	0.00713	0.00713	CcSEcCtD
Apraclonidine—Nervous system disorder—Vincristine—muscle cancer	0.00704	0.00704	CcSEcCtD
Apraclonidine—Dysgeusia—Etoposide—muscle cancer	0.00698	0.00698	CcSEcCtD
Apraclonidine—Fatigue—Dactinomycin—muscle cancer	0.00693	0.00693	CcSEcCtD
Apraclonidine—Pain—Dactinomycin—muscle cancer	0.00687	0.00687	CcSEcCtD
Apraclonidine—Eye pain—Doxorubicin—muscle cancer	0.0068	0.0068	CcSEcCtD
Apraclonidine—Irritability—Methotrexate—muscle cancer	0.00676	0.00676	CcSEcCtD
Apraclonidine—Feeling abnormal—Dactinomycin—muscle cancer	0.00662	0.00662	CcSEcCtD
Apraclonidine—Ill-defined disorder—Etoposide—muscle cancer	0.00661	0.00661	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00657	0.00657	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00654	0.00654	CcSEcCtD
Apraclonidine—Insomnia—Vincristine—muscle cancer	0.00649	0.00649	CcSEcCtD
Apraclonidine—Paraesthesia—Vincristine—muscle cancer	0.00645	0.00645	CcSEcCtD
Apraclonidine—Malaise—Etoposide—muscle cancer	0.00643	0.00643	CcSEcCtD
Apraclonidine—Abdominal pain—Dactinomycin—muscle cancer	0.00635	0.00635	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Vincristine—muscle cancer	0.0062	0.0062	CcSEcCtD
Apraclonidine—Fatigue—Vincristine—muscle cancer	0.00619	0.00619	CcSEcCtD
Apraclonidine—Pain—Vincristine—muscle cancer	0.00614	0.00614	CcSEcCtD
Apraclonidine—Constipation—Vincristine—muscle cancer	0.00614	0.00614	CcSEcCtD
Apraclonidine—Asthma—Methotrexate—muscle cancer	0.00613	0.00613	CcSEcCtD
Apraclonidine—Chest pain—Etoposide—muscle cancer	0.00607	0.00607	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00602	0.00602	CcSEcCtD
Apraclonidine—Discomfort—Etoposide—muscle cancer	0.00599	0.00599	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—muscle cancer	0.00592	0.00592	CcSEcCtD
Apraclonidine—Hypersensitivity—Dactinomycin—muscle cancer	0.00592	0.00592	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—muscle cancer	0.00587	0.00587	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Vincristine—muscle cancer	0.00587	0.00587	CcSEcCtD
Apraclonidine—Infection—Etoposide—muscle cancer	0.00578	0.00578	CcSEcCtD
Apraclonidine—Asthenia—Dactinomycin—muscle cancer	0.00576	0.00576	CcSEcCtD
Apraclonidine—Abdominal pain—Vincristine—muscle cancer	0.00567	0.00567	CcSEcCtD
Apraclonidine—Skin disorder—Etoposide—muscle cancer	0.00565	0.00565	CcSEcCtD
Apraclonidine—Diarrhoea—Dactinomycin—muscle cancer	0.0055	0.0055	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—muscle cancer	0.00549	0.00549	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—muscle cancer	0.00546	0.00546	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—muscle cancer	0.00546	0.00546	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—muscle cancer	0.00531	0.00531	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—muscle cancer	0.0053	0.0053	CcSEcCtD
Apraclonidine—Hypersensitivity—Vincristine—muscle cancer	0.00529	0.00529	CcSEcCtD
Apraclonidine—Paraesthesia—Etoposide—muscle cancer	0.00522	0.00522	CcSEcCtD
Apraclonidine—Dyspnoea—Etoposide—muscle cancer	0.00518	0.00518	CcSEcCtD
Apraclonidine—Somnolence—Etoposide—muscle cancer	0.00517	0.00517	CcSEcCtD
Apraclonidine—Asthenia—Vincristine—muscle cancer	0.00515	0.00515	CcSEcCtD
Apraclonidine—Vomiting—Dactinomycin—muscle cancer	0.00511	0.00511	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Etoposide—muscle cancer	0.00502	0.00502	CcSEcCtD
Apraclonidine—Fatigue—Etoposide—muscle cancer	0.00501	0.00501	CcSEcCtD
Apraclonidine—Pain—Etoposide—muscle cancer	0.00497	0.00497	CcSEcCtD
Apraclonidine—Constipation—Etoposide—muscle cancer	0.00497	0.00497	CcSEcCtD
Apraclonidine—Diarrhoea—Vincristine—muscle cancer	0.00491	0.00491	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—muscle cancer	0.0049	0.0049	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—muscle cancer	0.00487	0.00487	CcSEcCtD
Apraclonidine—Feeling abnormal—Etoposide—muscle cancer	0.00479	0.00479	CcSEcCtD
Apraclonidine—Nausea—Dactinomycin—muscle cancer	0.00477	0.00477	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Etoposide—muscle cancer	0.00476	0.00476	CcSEcCtD
Apraclonidine—Dizziness—Vincristine—muscle cancer	0.00475	0.00475	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—muscle cancer	0.00473	0.00473	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—muscle cancer	0.00473	0.00473	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—muscle cancer	0.00472	0.00472	CcSEcCtD
Apraclonidine—Abdominal pain—Etoposide—muscle cancer	0.0046	0.0046	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—muscle cancer	0.0046	0.0046	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—muscle cancer	0.00458	0.00458	CcSEcCtD
Apraclonidine—Vomiting—Vincristine—muscle cancer	0.00456	0.00456	CcSEcCtD
Apraclonidine—Dermatitis—Vincristine—muscle cancer	0.00452	0.00452	CcSEcCtD
Apraclonidine—Headache—Vincristine—muscle cancer	0.0045	0.0045	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—muscle cancer	0.00445	0.00445	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—muscle cancer	0.00442	0.00442	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—muscle cancer	0.00432	0.00432	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—muscle cancer	0.0043	0.0043	CcSEcCtD
Apraclonidine—Hypersensitivity—Etoposide—muscle cancer	0.00428	0.00428	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—muscle cancer	0.00427	0.00427	CcSEcCtD
Apraclonidine—Nausea—Vincristine—muscle cancer	0.00426	0.00426	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—muscle cancer	0.00426	0.00426	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—muscle cancer	0.00425	0.00425	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—muscle cancer	0.00421	0.00421	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—muscle cancer	0.00418	0.00418	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—muscle cancer	0.00418	0.00418	CcSEcCtD
Apraclonidine—Asthenia—Etoposide—muscle cancer	0.00417	0.00417	CcSEcCtD
Apraclonidine—Pruritus—Etoposide—muscle cancer	0.00411	0.00411	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—muscle cancer	0.00409	0.00409	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—muscle cancer	0.00402	0.00402	CcSEcCtD
Apraclonidine—Diarrhoea—Etoposide—muscle cancer	0.00398	0.00398	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—muscle cancer	0.00397	0.00397	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—muscle cancer	0.00396	0.00396	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—muscle cancer	0.00385	0.00385	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—muscle cancer	0.00385	0.00385	CcSEcCtD
Apraclonidine—Dizziness—Etoposide—muscle cancer	0.00385	0.00385	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—muscle cancer	0.00383	0.00383	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—muscle cancer	0.00379	0.00379	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—muscle cancer	0.00372	0.00372	CcSEcCtD
Apraclonidine—Vomiting—Etoposide—muscle cancer	0.0037	0.0037	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—muscle cancer	0.0037	0.0037	CcSEcCtD
Apraclonidine—Dermatitis—Etoposide—muscle cancer	0.00366	0.00366	CcSEcCtD
Apraclonidine—Headache—Etoposide—muscle cancer	0.00364	0.00364	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—muscle cancer	0.00363	0.00363	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—muscle cancer	0.00363	0.00363	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—muscle cancer	0.00363	0.00363	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—muscle cancer	0.00362	0.00362	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00361	0.00361	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—muscle cancer	0.00359	0.00359	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—muscle cancer	0.00359	0.00359	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—muscle cancer	0.00348	0.00348	CcSEcCtD
Apraclonidine—Infection—Methotrexate—muscle cancer	0.00346	0.00346	CcSEcCtD
Apraclonidine—Nausea—Etoposide—muscle cancer	0.00345	0.00345	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—muscle cancer	0.00343	0.00343	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—muscle cancer	0.00342	0.00342	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—muscle cancer	0.00338	0.00338	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—muscle cancer	0.00333	0.00333	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—muscle cancer	0.00331	0.00331	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—muscle cancer	0.00327	0.00327	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00317	0.00317	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—muscle cancer	0.00315	0.00315	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—muscle cancer	0.00315	0.00315	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—muscle cancer	0.00315	0.00315	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—muscle cancer	0.00313	0.00313	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00312	0.00312	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—muscle cancer	0.00311	0.00311	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—muscle cancer	0.00311	0.00311	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—muscle cancer	0.0031	0.0031	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—muscle cancer	0.00308	0.00308	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—muscle cancer	0.00302	0.00302	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00301	0.00301	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—muscle cancer	0.003	0.003	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—muscle cancer	0.003	0.003	CcSEcCtD
Apraclonidine—Pain—Methotrexate—muscle cancer	0.00298	0.00298	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—muscle cancer	0.00296	0.00296	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—muscle cancer	0.00293	0.00293	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—muscle cancer	0.00287	0.00287	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—muscle cancer	0.00285	0.00285	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—muscle cancer	0.00275	0.00275	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00275	0.00275	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—muscle cancer	0.00273	0.00273	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—muscle cancer	0.00271	0.00271	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—muscle cancer	0.00269	0.00269	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—muscle cancer	0.00268	0.00268	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.0026	0.0026	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—muscle cancer	0.0026	0.0026	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—muscle cancer	0.00258	0.00258	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—muscle cancer	0.00258	0.00258	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—muscle cancer	0.00257	0.00257	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—muscle cancer	0.0025	0.0025	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—muscle cancer	0.00249	0.00249	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00247	0.00247	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—muscle cancer	0.00246	0.00246	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—muscle cancer	0.00238	0.00238	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—muscle cancer	0.00238	0.00238	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—muscle cancer	0.0023	0.0023	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—muscle cancer	0.00222	0.00222	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—muscle cancer	0.00221	0.00221	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—muscle cancer	0.00219	0.00219	CcSEcCtD
Apraclonidine—Headache—Methotrexate—muscle cancer	0.00218	0.00218	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—muscle cancer	0.00216	0.00216	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—muscle cancer	0.00213	0.00213	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—muscle cancer	0.00207	0.00207	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—muscle cancer	0.00206	0.00206	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—muscle cancer	0.00199	0.00199	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—muscle cancer	0.00192	0.00192	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—muscle cancer	0.0019	0.0019	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—muscle cancer	0.00189	0.00189	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—muscle cancer	0.00179	0.00179	CcSEcCtD
